Home Bratislava Medical Journal 2014 Bratislava Medical Journal Vol.115, No.2, p.59-65, 2014

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.115, No.2, p.59-65, 2014

Title: Understanding cholesterol: high is bad but too low may also be risky – is low cholesterol associated with cancer?
Author: V. Simko, E. Ginter

Abstract: Cholesterol (CH) is a vital component of cell membranes and of their function. It is entirely justified to warn against haphazard aggressive CH lowering, especially now, when more effective CH-modifying medications are entering the market. Enormous success in lowering the human toll of atherosclerosis and cardiovascular disease (CVD) by treating abnormally elevated lipids may be off set by the therapeutic risk. There are warning reports that low cholesterol is associated with malignity. There is a pressing need to evaluate all reports related to the risk of low CH body stores. New cholesterol management guidelines presented by American professional cardiology societies in November 2013 have reinforced the need to critically evaluate the management with statins and with other CH lowering medications (Tab. 1, Fig. 3, Ref. 58).

Keywords: total cholesterol (CH), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), cardiovascular disease (CVD), hydroxy-methylglutaryl coenzyme A reductase (HMGCR), randomized control trial (RCT), cancer, statin, low cholesterol risk, lipid treatment guideline.
Year: 2014, Volume: 115, Issue: 2 Page From: 59, Page To: 65
doi:10.4149/BLL_2014_013


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.